FDA Approval Alert: The Need-to-Know | Ribociclib/NSAI in HR+/HER2- Stage II-III Early Breast Cancer
In September 2024, the FDA approved ribociclib plus an aromatase inhibitor as adjuvant treatment for patients with hormone receptor–positive, HER2-negative stage II and III early breast cancer at high risk of recurrence.